Barclays’s Puma Biotechnology PBYI Stock Holding History

Barclays’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,000	Closed	-$194K	–	7168
2019 Q1	$194K	Sell	5,000 -4,600	-48%	-$140K	﹤0.01%	4850
2018 Q4	$195K	Buy	+9,600	New	+$288K	﹤0.01%	4594
2018 Q3	–	Sell	-200	Closed	-$12K	–	7325
2018 Q2	$12K	Sell	200 -2,500	-93%	-$145K	﹤0.01%	6466
2018 Q1	$184K	Sell	2,700 -56,900	-95%	-$4.26M	﹤0.01%	4904
2017 Q4	$5.89M	Buy	59,600 +29,700	+99%	+$3.32M	﹤0.01%	1538
2017 Q3	$3.58M	Sell	29,900 -22,100	-43%	-$2.06M	﹤0.01%	1800
2017 Q2	$4.54M	Buy	52,000 +50,800	+4,233%	+$2.84M	﹤0.01%	1543
2017 Q1	$45K	Buy	+1,200	New	+$43.8K	﹤0.01%	5397
2015 Q2	–	Sell	-8,900	Closed	-$2.1M	–	7148
2015 Q1	$2.1M	Sell	8,900 -6,500	-42%	-$1.39M	﹤0.01%	2268
2014 Q4	$2.91M	Sell	15,400 -45,900	-75%	-$10.2M	﹤0.01%	2181
2014 Q3	$14.6M	Buy	+61,300	New	+$12.6M	0.01%	915

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's PBYI Position: Q2 2026 in Review

Barclays reduced its Puma Biotechnology (PBYI) stake by 20% in Q2 2026, selling an estimated $20.4K and leaving 11,202 shares worth $90.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4082.

Barclays first reported a position in PBYI in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.5M in Q3 2017. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

Barclays held 11,202 shares of Puma Biotechnology worth $90.8K as of Q2 2026.
Barclays sold 2,786 Puma Biotechnology shares in Q2 2026, an estimated $20.4K.
Puma Biotechnology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4082 holding.
Barclays first reported a position in Puma Biotechnology in Q2 2013 and has held it in 52 quarters since.
Barclays's Puma Biotechnology position peaked at $22.5M in Q3 2017.
161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.